Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the glioblastoma multiforme market grown over the years?

The market for glioblastoma multiforme has experienced remarkable growth in recent periods. Its size is forecasted to increase from $2.50 billion in 2024 to $2.71 billion in 2025, displaying a compound annual growth rate (CAGR) of 8.3%. This growth during the historical period can be credited to factors such as the rising occurrences of glioblastoma multiforme, improvements in healthcare infrastructure, heightened awareness, amplified access to superior treatments and therapies, as well as the growing elderly population.

What Is the forecasted market size and growth rate for the glioblastoma multiforme market?

The market size for glioblastoma multiforme is forecasted to exhibit robust growth in the coming years, reaching a worth of $3.69 billion in 2029, with a compound annual growth rate (CAGR) of 8.1%. The anticipated growth during this period is due to a rise in brain and other nervous system cancer cases, increased acceptance of surgical methods, heightened awareness, early disease detection, and a surge in research and development operations. Notable trends for the forecast period encompass progress in medical technology, developments in image-based techniques, individualized medicine, the use of AI in diagnosis, and advancements in technology and science.

Get your glioblastoma multiforme market report here!

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

What are the major factors driving growth in the glioblastoma multiforme market?

The anticipated increase in brain disorder instances is predicted to propel the glioblastoma multiforme market in the future. Brain disorders, which can cause cognitive, emotional, or physical limitations, are conditions that impact the brain’s structure or functionality. Factors such as an aging demographic, extended life expectancy, way of living, and enhanced diagnostic proficiency contribute to the upswing in brain disorder occurrences. Comprehending these disorders makes it possible to advance glioblastoma multiforme (GBM) research, paving the way for enhanced early detection, revolutionary treatment methods, and improved patient results. By examining neurological disorders, researchers can find gene and molecule associations that play a role in the development of GBM. As an example, Dementia Australia, a non-profit Australian organization, stated in February 2025 that approximately 433,300 Australians are living with dementia. This figure is expected to increase to 812,500 by 2054. Furthermore, younger-onset dementia affected around 29,000 Australians in 2025, and that number is estimated to increase to 41,000 by 2054. Consequently, the surge in brain disorder instances will boost the glioblastoma multiforme market’s growth.

What key areas define the segmentation of the global glioblastoma multiforme Market?

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

What are the top market players propelling the growth of the glioblastoma multiforme industry?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Which trends are expected to transform the glioblastoma multiforme market?

Leading firms in the glioblastoma multiforme market are concentrating on the creation of advanced therapeutic solutions such as CAR T-cell therapies, with the objective of fulfilling the unaddressed healthcare needs in deadly cancer cases. CAR T-cell therapies are an immunotherapy type in which the patient’s T-cells are altered to more effectively target and destroy cancer cells. For instance, Chimeric Therapeutics Limited, a biotech firm based in Australia, initiated a Phase IB clinical trial in June 2023 for CHM 1101 (CLXT CAR T) therapy, targeted at recurrent or progressive glioblastoma multiforme (GBM). The multi-center trial’s goal is to examine the safety and efficacy of the therapy and establish the recommended dose for Phase 2. Preliminary results from Phase 1a indicated disease stability, and the trial will build upon this data to facilitate further progress. The company’s strategy is to utilize the trial data to plan a registration trial and solicit regulatory feedback.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21191

What regions are dominating the glioblastoma multiforme market growth?

North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Bleeding Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

Bleeding Disorder Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bleeding-disorder-testing-global-market-report

Small Cell Lung Cancer Therapeutics Global Market Report 2025

https://thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: